THE Generic and Biosimilar Medicines Association (GBMA) Board yesterday announced the resignation of ceo Belinda Wood after her five years working with the peak industry body.
GBMA hailed her tenure, saying she had been pivotal in the signing of, and subsequent extension to, the strategic agreement with Government, helping position the GBMA as "the premier association for biosimilars and generics".
GBMA chair Allan Tillack said "Belinda has steered the GBMA through its most significant period of change. Her collaborative leadership and personal integrity has seen GMiA evolve into the GBMA we know today".
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Oct 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Oct 17